DFO經皮給藥的可行性研究

Abstract

海洋性貧血病人需長期接受輸血以維持生命，然而長期輸血容易導致病人體 內三價鐵離子含量過高而產生鐵中毒的現象，鐵中毒慣例上採用deferoxamine mesylate(Desferal, DFO)連續式點滴或皮下注射以螯合治療，但病患容易因為疼痛 而產生排斥感，使治療效果不佳，所以我們希望能夠改變藥物劑型，企圖以經皮 給藥的方式來取代注射治療，本實驗的目的即是評估將DFO 製成貼劑貼在皮膚上 給藥的可行性，將選擇基質式經皮吸收系統，使DFO 能穿過皮膚，藉以設計DFO 貼片。此貼片希望能夠以一定傳送速率讓藥穿過皮膚到達循環系統，而達全身性 治療效果。本實驗係以商用感壓膠為基質，探討DFO 在其中的藥物釋放情形，以 開發為經皮吸收貼劑。

The goal of this study is to help thalassemia patients, who chronically require blood transfusions to keep alive. However, such long-term transfusions can easily lead to a build-up of trivalent iron and produce an iron overload condition. To treat iron overload, the patients usually receive intravenous or subcutaneous deferoxamine mesylate (DFO) regularly. But, because of the pain the patients may resist taking drug, so the effects of treatment are not very good. Consequently, we hope to be able to change the method of delivering DFO—we want to see if we can replace the injection method with transdermal drug delivery. The preliminary goal of the study, therefore, is to assess the feasibility of designing and fabricating a DFO patch using an adhesive dispersion-type transdermal drug delivery system. It is hoped that it can let the drug pass through the skin at a fixed rate of speed and reach the circulation system, from where it can spread its therapeutic effect throughout the body. In this research, we choose the commercial pressure sensitive adhesives to be the drug reservoirs and observe the release profile of DFO in the adhesives in order to develop and design transdermal patchs.